EGX: MCRO Statistics

Total Valuation

Macro Group Pharmaceuticals (Macro Capital) S.A.E has a market cap or net worth of EGP 1.44 billion. The enterprise value is 1.59 billion.

Market Cap	1.44B
Enterprise Value	1.59B

Important Dates

The next estimated earnings date is Sunday, March 2, 2025.

Earnings Date	Mar 2, 2025
Ex-Dividend Date	n/a

Share Statistics

Macro Group Pharmaceuticals (Macro Capital) S.A.E has 570.21 million shares outstanding. The number of shares has increased by 0.27% in one year.

Current Share Class	n/a
Shares Outstanding	570.21M
Shares Change (YoY)	+0.27%
Shares Change (QoQ)	-0.02%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	12.01%
Float	241.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.62
PB Ratio	28.86
P/TBV Ratio	62.58
P/FCF Ratio	47.82
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.65
EV / Sales	6.24
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	52.85

Financial Position

The company has a current ratio of 1.29, with a Debt / Equity ratio of 5.50.

Current Ratio	1.29
Quick Ratio	0.62
Debt / Equity	5.50
Debt / EBITDA	n/a
Debt / FCF	9.12
Interest Coverage	-8.21

Financial Efficiency

Return on equity (ROE) is -169.61% and return on invested capital (ROIC) is -50.29%.

Return on Equity (ROE)	-169.61%
Return on Assets (ROA)	-32.17%
Return on Capital (ROIC)	-50.29%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.34
Inventory Turnover	1.45

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.10% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-23.10%
50-Day Moving Average	2.24
200-Day Moving Average	2.18
Relative Strength Index (RSI)	57.05
Average Volume (20 Days)	9,960,009

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Macro Group Pharmaceuticals (Macro Capital) S.A.E had revenue of EGP 255.68 million and -436.86 million in losses. Loss per share was -0.77.

Revenue	255.68M
Gross Profit	62.64M
Operating Income	-383.03M
Pretax Income	-462.28M
Net Income	-436.86M
EBITDA	-375.69M
EBIT	-383.03M
Loss Per Share	-0.77

Full Income Statement

Balance Sheet

The company has 123.59 million in cash and 275.14 million in debt, giving a net cash position of -151.56 million or -0.27 per share.

Cash & Cash Equivalents	123.59M
Total Debt	275.14M
Net Cash	-151.56M
Net Cash Per Share	-0.27
Equity (Book Value)	50.05M
Book Value Per Share	0.09
Working Capital	105.53M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 37.26 million and capital expenditures -7.09 million, giving a free cash flow of 30.17 million.

Operating Cash Flow	37.26M
Capital Expenditures	-7.09M
Free Cash Flow	30.17M
FCF Per Share	0.05

Full Cash Flow Statement

Margins

Gross margin is 24.50%, with operating and profit margins of -149.81% and -170.86%.

Gross Margin	24.50%
Operating Margin	-149.81%
Pretax Margin	-180.80%
Profit Margin	-170.86%
EBITDA Margin	-146.94%
EBIT Margin	-149.81%
FCF Margin	11.80%

Dividends & Yields

Macro Group Pharmaceuticals (Macro Capital) S.A.E does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.27%
Shareholder Yield	-0.27%
Earnings Yield	-30.43%
FCF Yield	2.09%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Macro Group Pharmaceuticals (Macro Capital) S.A.E has an Altman Z-Score of -0.12. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.12
Piotroski F-Score	n/a